Expanding Immunotherapy to Cervical Cancer
The FDA has expanded the use of the immunotherapeutic pembrolizumab to treat certain patients with cervical cancer. The U.S....
Progress Against Cancer
The FDA has expanded the use of the immunotherapeutic pembrolizumab to treat certain patients with cervical cancer. The U.S....
The FDA has expanded the use of pembrolizumab to treat certain patients with non-Hodgkin lymphoma. The U.S. Food and...
The FDA decision means tisagenlecleucel (Kymriah) is now approved for certain types of non-Hodgkin lymphoma and acute lymphoblastic leukemia....
The FDA has approved a combination of ipilimumab and nivolumab for treating intermediate- or poor-risk, previously untreated advanced renal...
An FDA-approved precision medicine treatment is for certain patients with metastatic lung cancer with a specific BRAF mutation. The...
The U.S. Food and Drug Administration (FDA) recently approved expanding the use of the immunotherapeutic durvalumab (Imfinzi) to include...
A new hormone therapy is the first treatment to be approved because it was found to markedly delay the...
The FDA has expanded the use of a molecularly targeted therapeutic to include patients with multiple myeloma. The U.S....
The FDA has approved the molecularly targeted therapeutic olaparib for treating patients who have HER2-negative breast cancer and who...
The FDA has expanded the use of a CD30-targeted antibody?drug conjugate to include two additional types of lymphoma. The...